Mediar Therapeutics focuses on neutralizing fibrosis-driving pathways with human IgG1 antibodies that inhibit specific extracellular proteins. Its lead candidate, MTX-474, an EphrinB2 antagonist, is now in a 90-patient global Phase 2a trial (EncompaSSc) for systemic sclerosis. MTX-463, a WISP1-targeting antibody partnered with Eli Lilly, is enrolling patients in a Phase 2a study for idiopathic pulmonary fibrosis after completing Phase 1. A third program, MTX-439, a SMOC2 antagonist for chronic kidney disease-associated fibrosis, is moving toward Phase 1 in the first half of 2026. Management reports that, including the latest financing and the Lilly partnership, the company has secured approximately $175 million to date, providing runway to advance all three assets through early and mid-stage clinical trials. Mediar’s strategy combines novel targets, blood-based biomarkers, and well-characterized antibody modalities to enable a potential precision-medicine approach in fibrotic diseases.

Total raised

$161M

Funding rounds

3

Latest round

Series B

Latest activity

Jan 2026